Interferon treatment of hepatitis C virus infection: From basic biology to clinical application

Norihiro Furusyo, Masayuki Murata, Jun Hayashi

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)


Tremendous progress has been made in the field of antiviral treatment for hepatitis C virus (HCV) infection since the identification of the virus in 1989. Although early treatment regimens with interferon (IFN) alone achieved only limited success, the addition of the broad-spectrum antiviral agent ribavirin has greatly improved response. The primary goal of treatment for HCV infection-viral eradication-is best achieved when the viral level is reduced substantially during the early phase of treatment.Viral eradication is expressive of sustained virological response, the benefits of which are multifactorial and include improved hepatic histology: a decreased occurrence of hepatocellular carcinoma or liver failure and a lower probability of liver-related mortality. Treatment of HCV infection with the current "gold standard" of care-pegylated IFN in combination with ribavirin-is associated with an approximately 50% overall rate of viral eradication, a great improvement over previous IFN treatment regimens. However, more effective and better-tolerated treatments are needed for patients with unfavorable treatment profiles, such as genotype 1, a high viral level at baseline, hepatic steatosis, and poor adherence to treatment due to severe side effects.

Original languageEnglish
Title of host publicationHepatitis C Virus Disease
Subtitle of host publicationImmunobiology and Clinical Applications
PublisherSpringer New York
Number of pages20
ISBN (Print)9780387713755
Publication statusPublished - 2008

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Interferon treatment of hepatitis C virus infection: From basic biology to clinical application'. Together they form a unique fingerprint.

Cite this